BRAF and melanoma: Nonetheless, the key DREAMseq study found that initial treatment with combination ICI therapy is significantly better than initial treatment with targeted therapy against BRAF and MEK, even in patients with BRAF-mutated melanomas (Atkins et al., 2023).